- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
A highly sensitive, non-invasive liquid biopsy for hematologic malignancies, analyzing both cfDNA and cfRNA to detect mutations, fusions, and immune signatures—without the need for bone marrow biopsy.
A next-generation liquid biopsy designed specifically for patients with hematologic malignancies. This pan-cancer assay utilizes both cell-free DNA (cfDNA) and cell-free RNA (cfRNA) obtained from peripheral blood or cerebrospinal fluid (CSF) to deliver an advanced molecular profile without the need for bone marrow biopsy.
Through high-sensitivity NGS, the test identifies a broad range of clinically relevant genomic alterations including gene mutations, fusion transcripts, chromosomal abnormalities, and copy number variations. It also includes B-cell and T-cell clonality analysis, HLA genotyping, viral RNA detection (EBV, HTLV-1, TTV), and therapeutic monitoring features such as MRD assessment and relapse prediction.
GTC’s Liquid Trace® Hematology Profile is a highly sensitive, pan-cancer test that evaluates circulating cell-free (cf) RNA and DNA and provides highly informative data that can be used for diagnosis, evaluation of the host immune response, and identification of biomarkers useful for predicting response to various therapies.
GTC’s Liquid Trace can significantly reduce the need for bone marrow biopsies for hematology patients. Furthermore, the test can detect chromosomal abnormalities, translocations, and gene amplifications.
By combining cfDNA and cfRNA analysis, Liquid Trace®: Hematology offers deeper insight into the disease biology, immune environment, and tumor evolution making it an ideal tool for initial diagnosis, therapeutic guidance, or longitudinal monitoring in leukemia, lymphoma, myeloma, and related disorders.
Liquid Trace® can detect all types of hematologic cancers including:
Many conventional liquid biopsy tests are dependent solely on cfDNA analysis, which presents multiple challenges. These include variations in DNA shedding between tumors as well as low sensitivity (especially in early-stage cancer), difficulty in detecting fusion genes (i.e., chromosomal translocations leading to the expression of chimeric mRNA from two genes), and inability to detect the numerous biological processes that modify RNA expression levels, such as alternative splicing, stability, and allele-specific methylation. The latter limitation is critically important as recent studies have shown that RNA testing provides another level of biological information regarding the tumor and its microenvironment.
Studies have found RNA sequencing to be more sensitive for some types of mutations, likely because cancer cells typically contain one copy of mutated DNA but numerous copies of RNA. This research is consistent with GTC’s findings that cfRNA has increased sensitivity over cfDNA alone. More specifically, cfRNA allows GTC’s Liquid Trace to detect more mutations and fusions in hematologic and solid tumor samples, which may be undetected with conventional cfDNA.
Sensitivity is 0.1 to 0.01 for non-hot spot, 0.01 to 0.001 for hotspot and <0.001 for tumor informed or prior Hx.
For DNA, QNS is rare (<0.1%), but it is higher for RNA (Good DNA results but poor RNA results. Of course, if we receive 3 ml of plasma (6 ml blood), the sample is QNS for performing RNA testing.
GTC uses AI in every step of our analysis, leading to daily discoveries that can help improve patient care.
Once the data are offloaded from the sequencer, our AI:
Real-world applications of our genomic testing
We provide a selection of real-world case studies that demonstrate the clinical utility and diagnostic impact of our genomic tests. Click the button below to explore individual cases and see how Liquid Trace® contributes to precision oncology in practice.
Our case study list is continuously updated as new clinical examples become available. We encourage you to revisit this page regularly to explore the latest insights and applications of our genomic testing in real-world settings.
Peripheral blood: 10 mL in an EDTA tube is required.
Important: RNA stability is 48-72 hours from blood draw. DNA stability is 7 days from blood draw. Samples received beyond 72 hours may include only DNA results.
CSF: 7-10 mL is optimal (5 mL minimum).
Important: Ship as soon as possible (overnight). Do not use collection devices with anti-coagulants. Clear tubes.
This is a brief overview of the sample requirements for this test. For complete and detailed instructions regarding specimen collection, handling, and submission, please download the full sample guidelines by clicking the button below.
Specimen Preparation and Shipping Guidelines
Use the Hematology Transport Kit
For blood samples:
Important: RNA stability is 48-72 hours from blood draw. DNA stability is 7 days from blood draw. Samples received beyond 72 hours may include only DNA results.
Fill out the form to request kits. Please refer to the Specimen Requirements page for more details.
*GTC will need to set you up in our system if this is your first order.
